Novel Structural Hybrids on the Base of Benzofuroxans and Furoxans. Mini-Review

Curr Top Med Chem. 2017;17(9):986-1005. doi: 10.2174/1568026616666160927145822.

Abstract

Hybrid drug strategy is based on the combination of two or more pharmacophores into a new chemical entity to improve the properties of the original compounds or to obtain double action of resulting molecule. Hybrid molecules, comprised of some pharmacophore and nitric oxide (NO) donor moiety, constitute one of the more promising approaches for the design of drugs. Furoxans and benzofuroxans are considered NO releasing prodrugs and are of great interest for researchers. In this review we will focus on furoxan and benzofuroxan hybrids described in literature during the last years (from 2005 to 2016).

Keywords: Benzofuroxan; Furoxan; Hybrid; NO-donor; Pharmacophore..

Publication types

  • Review

MeSH terms

  • Animals
  • Benzoxazoles / chemistry
  • Benzoxazoles / metabolism
  • Benzoxazoles / pharmacology*
  • Humans
  • Molecular Structure
  • Nitric Oxide / chemistry
  • Nitric Oxide / metabolism*
  • Nitric Oxide Donors / chemistry
  • Nitric Oxide Donors / metabolism
  • Nitric Oxide Donors / pharmacology*
  • Oxadiazoles / chemistry
  • Oxadiazoles / metabolism
  • Oxadiazoles / pharmacology*
  • Prodrugs / chemistry
  • Prodrugs / metabolism
  • Prodrugs / pharmacology*

Substances

  • Benzoxazoles
  • Nitric Oxide Donors
  • Oxadiazoles
  • Prodrugs
  • furoxans
  • Nitric Oxide
  • benzofuroxan